Xeris Pharmaceuticals, Inc. announced an exclusive agreement with Clinigen Group plc to manage the supply and distribution of Gvoke outside of the United States where Gvoke is not currently licensed. With Clinigen's global infrastructure and expertise in the distribution of important unlicensed medicines, can enable people with diabetes around the world to access Gvoke.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.995 USD | +0.76% | +5.85% | -15.32% |
May. 09 | Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.32% | 294M | |
+33.27% | 709B | |
+30.77% | 595B | |
-1.89% | 367B | |
+20.22% | 334B | |
+5.35% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.32% | 171B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Pharmaceuticals Signs Exclusive Agreement with Clinigen to Supply and Distribute Gvoke™ Outside the U.S on Named Patient Basis